Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 75, Issue 2, 2016, Pages 374-381

  Tashkin, Donald P ^a   Volkmann, Elizabeth R ^a   Tseng, Chi Hong ^a   Kim, Hyun J ^a   Goldin, Jonathan ^a   Clements, Philip ^a   Furst, Daniel ^a   Khanna, Dinesh ^b   Kleerup, Eric ^a   Roth, Michael D ^a   Elashoff, Robert ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; CARBON MONOXIDE;

ADULT; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSING CAPACITY FOR CARBON MONOXIDE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG TOLERABILITY; FEMALE; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PULMONARY FIBROSIS; RADIOGRAPHY; REGRESSION ANALYSIS; STATISTICS AND NUMERICAL DATA; THORAX RADIOGRAPHY; VITAL CAPACITY;

ADULT; CARBON MONOXIDE; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PULMONARY DIFFUSING CAPACITY; PULMONARY FIBROSIS; RADIOGRAPHY, THORACIC; REGRESSION ANALYSIS; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84954348461     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206076     Document Type: Article

References (31)

1. Tashkin DP, Elashoff R, Clements PJ, et al.; for the Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
2. Roth MD, Tseng CH, Clements PJ, et al.; for the Scleroderma Lung Study Research Group. Predicting Lung function and treatment outcomes in scleroderma-related interstitial lung disease. Arthritis Rheum 2011;63:3078-85.
3. Goldin J, Elashoff R, Kim HJ, et al. Treatment of scleroderma interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo. Chest 2009;136:1333-40.
4. Kim HJ, Brown M, Elashoff R, et al. Quantitative computer-aided assessment of one-year changes in fibrosis and other interstitial lung disease abnormalities in HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiology 2011;21:2455-65.
5. Khanna D, Tseng C-H, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study placebo group. Arthritis Rheum 2011;63:3078-85.
6. Goh NSL, Desai SR, Veeraraghaven S, et al. Interstitial lung disease in systemic sclerosis. A simple staging system. Am J Respir Crit Care Med 2008;177: 1248-54.
7. Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013;52:155-60.
8. Kim HJ, Li G, Gjertson D, et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol 2008;15:1004-16.
9. Kim HJ, Tashkin DP, Clements P, et al. Computer aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exper Rheum 2010;28:S26-35.
10. Villaba WO, Sampaio-Barros PD, Pereira MC, et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007;131:217-22.
11. McNearney TA, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007;57:318-26.
12. Beretta L, Santaniello A, Lemos A, et al. Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology (Oxford) 2007;46:296-301.
13. Warrick JH, Bhalla M, Schabel SI, et al. High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991;18:1520-8.
14. Diot E, Boissinot E, Asquier E, et al. Relationship between abnormalities on highresolution CT and pulmonary function in systemic sclerosis. Chest 1998;114:1623-9.
15. Bellia M, Cannizzaro F, Scichilone N, et al. HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities. Radiol Med 2009;114:190-203.
16. Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008;134:358-67.
17. Ooi GC, Mok MY, Tsang KW, et al. Interstitial lung disease in systemic sclerosis. Acta Radiol 2003;44:258-64.
18. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997;40:1229-36.
19. Tashkin DP, Roth M, Furst D, et al.; for the Scleroderma Lung Study II Research Group. Double-blind comparison of mycophenolate mofetil and oral cyclophosphamide for treatment of scleroderma-related interstitial lung disease (Scleroderma Lung Study [SLS] II): Rational, design, methods, baseline characteristics and patient disposition. American Thoracic Society International Conference; Am J Respir Crit Care Med Abstracts Issue 2013, A2921.
20. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159:179-87.
21. Crapo RO, Morris AH, Clayton PD, et al. Lung volumes in healthy nonsmoking adults. Bull Eur Physiolpathol Respir 1982;18:419-25.
22. Neas LM, Schwartz J. The determinants of pulmonary diffusing capacity in a national sample of U.S. adults. Am J Respir Crit Care Med 1996;153: 656-4.
23. MacIntyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. (ATS/ERS Task Force: Standardisation of Lung Function Testing). Eur Respir J 2005;26:720-35.
24. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.
25. Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD 2004;1:1-8.
26. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis (SSc): an assessment of inter-observer variability in three independent studies. J Rheumatol 1993;20:1892-6.
27. Steen VC, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
28. Furnival GM, Wilson RW. Regression by Leaps and Bounds. Technometrics 1974;16:499-511.
29. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
30. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54: 3962-70.
31. Steyerberg EW, Harrell FE, Borsboom JG, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001;54:774-81.